Therapeutic and adverse effects of standard-dose and low-dose meglumine antimoniate during systemic treatment of Syrian cutaneous leishmaniasis patients. J Pak Assoc Dermatol [Internet]. 2016 Dec. 2 [cited 2026 Jul. 28];24(2):115-21. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/189